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ARTICLE
A Genomewide Screen for Late-Onset Alzheimer Disease
in a Genetically Isolated Dutch Population
Fan Liu,* Alejandro Arias-Va´squez,* Kristel Sleegers, Yurii S. Aulchenko, Manfred Kayser,
Pascual Sanchez-Juan, Bing-Jian Feng, Aida M. Bertoli-Avella, John van Swieten,
Tatiana I. Axenovich, Peter Heutink, Christine van Broeckhoven, Ben A. Oostra,
and Cornelia M. van Duijn
Alzheimer disease (AD) is the most common cause of dementia. We conducted a genome screen of 103 patients with
late-onset AD who were ascertained as part of the Genetic Research in Isolated Populations (GRIP) program that is
conducted in a recently isolated population from the southwestern area of The Netherlands. All patients and their 170
closely related relatives were genotyped using 402 microsatellite markers. Extensive genealogy information was collected,
which resulted in an extremely large and complex pedigree of 4,645 members. The pedigree was split into 35 subpedigrees,
to reduce the computational burden of linkage analysis. Simulations aiming to evaluate the effect of pedigree splitting
on false-positive probabilities showed that a LOD score of 3.64 corresponds to 5% genomewide type I error. Multipoint
analysis revealed four significant and one suggestive linkage peaks. The strongest evidence of linkage was found for
chromosome 1q21 (heterogeneity LOD at marker D1S498). Approximately 30 cM upstream of this locus,[HLOD]p 5.20
we found another peak at 1q25 ( at marker D1S218). These two loci are in a previously established linkageHLODp 4.0
region. We also confirmed the AD locus at 10q22-24 ( at marker D10S185). There was significant evidenceHLODp 4.15
of linkage of AD to chromosome 3q22-24 ( at marker D3S1569). For chromosome 11q24-25, there wasHLODp 4.44
suggestive evidence of linkage ( at marker D11S1320). We next tested for association between cognitiveHLODp 3.29
function and 4,173 single-nucleotide polymorphisms in the linked regions in an independent sample consisting of 197
individuals from the GRIP region. After adjusting for multiple testing, we were able to detect significant associations for
cognitive function in four of five AD-linked regions, including the new region on chromosome 3q22-24 and regions
1q25, 10q22-24, and 11q25. With use of cognitive function as an endophenotype of AD, our study indicates the that
the RGSL2, RALGPS2, and C1orf49 genes are the potential disease-causing genes at 1q25. Our analysis of chromosome
10q22-24 points to the HTR7, MPHOSPH1, and CYP2C cluster. This is the first genomewide screen that showed significant
linkage to chromosome 3q23 markers. For this region, our analysis identified the NMNAT3 and CLSTN2 genes. Our
findings confirm linkage to chromosome 11q25. We were unable to confirm SORL1; instead, our analysis points to the
OPCML and HNT genes.
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Alzheimer disease (AD) is a progressive neurodegenerative
disorder that accounts for the vast majority of dementia.
The population prevalence of the disease rises steeply with
age from !2% at age 65 years to 135% after age 90 years.1,2
Family history is an important indicator of risk of AD,
and, in a large number of families, the disease segregates
as an autosomal dominant trait. The heritability for AD
was recently estimated to be 79%.3 Several dominant mu-
tations have been identified, including mutations in the
presenilin 1 (PSEN1 [MIM 104311]),4 presenilin 2 (PSEN2
[MIM 600759]),5,6 and amyloid precursor protein (APP
[MIM 104760]) genes.7 A common polymorphism (4) in
the gene encoding apolipoprotein E (APOE [MIM 107741])
increases susceptibility to both early- and late-onset AD.8,9
These four genes together explain less than a quarter of
the disease prevalence, indicating that additional genetic
risk factors remain to be identified.10,11 In addition to
APOE, various candidate genes were reported to be asso-
ciated with late-onset AD. In most cases, findings have
not been consistently replicated.12,13 A large meta-anal-
ysis of all genes studied so far pinpointed 13 potential
AD-susceptibility genes: angiotensin I converting enzyme
(ACE [MIM 106180]); cholinergic receptor, nicotinic, beta
2 (CHRNB2 [MIM 118507]); cystatin C (CST3 [MIM
604312]); estrogen receptor 1 (ESR1 [MIM 133430]);
glyceraldehyde-3-phosphate dehydrogenase, spermato-
genic (GAPDHS [MIM 609169]); insulin-degradingenzyme
(IDE [MIM 146680]); 5,10-methylenetetrahydrofolate re-
ductase (MTHFR [MIM 607093]); nicastrin (NCSTN [MIM
605254]); prion protein (PRNP [MIM 176640]); PSEN1;
Figure 1. The entire pedigree with 4,645 members, including 103 patients with late-onset AD, from the GRIP population. Men are
represented with squares and women with circles. Black dots represent marriage nodes. Affected individuals are represented in black.
Unknown affection status is represented with yellow. For simplicity, unaffected relatives of the patients are not shown. This figure was
drawn using Pedfiddler version 0.5.
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Table 1. Genealogic Characteristics of 103 Patients with Late-Onset AD
and Their Relatives
Characteristic Valuea
Complete genealogy:
No. of family members 4,645
No. of generations 18
Average no. of consanguineous loops per patient 71.7 (0–677)
Average no. of meioses in a consanguineous loop (0–29)9.9 1.2
Mean inbreeding coefficient #100 (0–3.2).39 .73
Average no. of lines of descent between a pair of patients (0–2,673)141.7
Average no. of meioses separating a pair of patients (0–34)17.1 1.6
Mean kinship coefficient #100 (0–26.4).18 1.06
After clustering patients into subpedigrees:
No. of subpedigrees 35
No. of founders 564 (46.0)
No. of females 630 (51.3)
Mean pedigree size 29.6 (18–75)
Mean no. of generations 7.5 (6–10)
Mean no. of genotyped individuals per pedigree 7.8 (2–14)
Mean no. of patients per pedigree 2.9 (2–6)
a Values in parentheses indicate range or percentage.
Table 2. Age-Dependent Liability Classes and Penetrances
Liability
Class
Age
(years)
Population
Prevalencea Penetrance
No. of
Patients
No. of Unaffected
Relatives
1 !65 !.02 .00 0 129
2 65–69 .02 .09 4 6
3 70–74 .05 .23 22 11
4 75–79 .09 .46 32 14
5 80–84 .23 .99 30 8
6 85–89 .35 .99 24 1
7 90 1.35 .99 0 1
a Obtained from the Rotterdam Study.1
transferrin (TF [MIM 190000]); transcription factor A,
mitochondrial (TFAM [MIM 600438]); and tumor necro-
sis factor (TNF [MIM 191160]).14 Furthermore, genome
screens targeting AD loci have been conducted. As re-
viewed online by the Alzheimer Research Forum, the rep-
licated regions from previous genome screens include
1p36, 1q21-31, 2p23-24, 4q35, 5p13-15, 6p21, 6q15-16,
6q25-27, 9p21-22, 10q21-22, 10q25, 12p11-12, 19q13,
21q21-22, and Xp11-21.9,15–29 Several genes have been sug-
gested to explain the linkage to chromosome 9, 10, 12,
and 19, but, so far, these genes also remain to be con-
firmed. Finally, there is evidence of linkage to chromo-
some 11,22 which was explained recently by the identifi-
cation of SORL1 (MIM 602005).30
Each of the established loci for AD (APP, PSEN1, PSEN2,
and APOE) was initially localized by linkage analyses.
However, pedigrees suitable for localizing genes have be-
come scarce, particularly for late-onset forms of AD. Ge-
netically isolated populations provide opportunities for
linkage analysis. With use of genealogical records, ex-
tended pedigrees can be constructed. Furthermore, the
complexity of disease may be reduced in terms of num-
ber of genes involved, particularly for rare Mendelian
forms.31,32 Linkage analysis of complex traits has been used
successfully in Iceland for complex diseases such as type
2 diabetes and stroke,33,34 whereas, for AD, genome screens
have been conducted successfully with Caribbean Hispan-
ics.35 We have followed this approach in a genetically iso-
lated community from the southwestern area of The Neth-
erlands, as part of the Genetic Research in Isolated Pop-
ulations (GRIP) program.36 A total of 103 patients with
late-onset AD were ascertained and were included in a
large pedigree on the basis of genealogical records. In this
study, we present a genomewide screen of these families.
The linkage analysis was followed by an association study
of cognitive function in a series of 197 unrelated and non-
demented people from the GRIP region who were exten-
sively characterized by a cognitive battery. To further in-
vestigate the evidence of linkage, the regions identified in
the linkage study were characterized with a dense panel
of SNPs. Decline in cognitive function, particularly mild
cognitive impairment, is an early predictor of AD,37–39 and
the heritability of cognitive function is as high as 56%,
which suggests that cognition is a valuable endopheno-
type.40–42 Further, memory function was found to be an
endophenotype for families multiply affected with AD.43
Material and Methods
Population and Genealogy
This study was performed within the framework of the previously
described GRIP program.32,44,45 The Medical Ethics Committee of
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Table 3. LOD Scores and
Corresponding Genomewide
Type I Error Rates
LOD HLOD
Type I Error Rate
(%)
4.08 4.08 1
3.64 3.64 5
3.24 3.24 10
2.11 2.11 50
NOTE.—Values are based on 100
simulations.
Figure 2. The 35 subpedigrees obtained by applying a kinship-
partitioning algorithm to the entire pedigree. The legend is avail-
able in its entirety in the online edition of The American Journal
of Human Genetics.
the Erasmus Medical Center approved study protocol. The GRIP
population is a genetically isolated community in the south-
western area of The Netherlands. Fewer than 400 individuals were
present in the region in the middle of the 18th century. Consid-
erable population growth occurred in 1850–1900, as was the case
in many European populations. An estimated 20,000 descen-
dants of the population are now scattered over eight adjacent
communities. There was minimal immigration. The genealogical
database currently contains information about 107,091 people
spanning 23 generations. Residents in the GRIP area are generally
related via multiple lines of descent and are inbred via multiple
consanguineous loops.45
Patients with AD were traced through general practitioners,
neurologists, and nursing-home physicians. Data relevant for the
diagnosis of AD were collected by a research physician, and the
diagnosis of AD was verified by two independent neurologists
with criteria of the National Institute of Neurological and Com-
municative Diseases and Stroke/Alzheimer’s Disease and Related
Disorders Association.46 Data about the presence of AD, parkin-
sonism, essential tremor, and dementia were collected for first-,
second-, and third-degree relatives by means of a family-history
questionnaire. First-degree relatives also underwent a brief neu-
rological examination. All patients and their relatives who were
invited to participate in our study provided informed consent. A
total of 112 probable patients with late-onset AD (age at onset
65 years, mean age [SD] at onset years) and 170 un-75 5.3
affected first-degree relatives (mean age years; range63.5 13.1
40–102 years) were ascertained.
Tracing the genealogy of the 112 probable patients with late-
onset AD, we were able to include 103 patients in a single pedigree
containing 4,645 individuals in 18 generations, as depicted in
figure 1. The other nine patients were singletons and therefore
were not included in the linkage analysis. This large pedigree
showed multiple, distant lines of descent and consanguineous
loops (table 1). The average kinship coefficient among patients
was 0.0018. This value is between a third cousin once removed
and a fourth cousin. Using such a pedigree in linkage analysis is
computationally impossible. A common approach to reduce the
computational complexity is to split the large pedigree into
smaller and computable units. For this purpose, we used a kinship
clustering method that is similar to the maximal-cliques-parti-
tioning method proposed by Falchi et al,47 and we added a re-
striction that the resulting subpedigrees have no more than 35
bits, where the bit size is twice the number of founders minus
the number of nonfounders. Our software for splitting large ped-
igrees, PedCut, is available, free of charge, at the MGA Web site.
We further studied a series of 197 individuals who were not
related withini 5 generations and were not related to the patients
with AD. The average age of these people was years;31.2 6.4
51% were female. These individuals were evaluated with use of
an extensive cognitive battery.48 In brief, the selection of tests
included the 15-word test, the color word card of the Stroop Color
Word test, part B of the Trail making test (TMTB), and the verbal
fluency test. These tests were selected to target early cognitive
problems related to AD. From the 15-word test, we derived three
scores for further analysis—that is, learning (or working memory),
delayed recall, and recognition. The verbal fluency test consists
of two subdomains: semantic fluency and phonological fluency.
The performance of each individual on each test was scored quan-
titatively. Power calculation showed that this sample has 80%
power to detect a SNP explaining 4% of phenotypic variance with
an a of .05.
Genotyping
For all patients and their 170 first-degree relatives, DNA was ex-
tracted from peripheral leukocytes following a standard proto-
col.49 Elsewhere, mutations in the APP, PSEN1, and PSEN2 genes
were excluded as AD-causing genes.36 The APOE genotype was
determined in all DNA samples by use of TaqMan allelic discrim-
ination technology on an ABI Prism 7900HT Sequence Detection
System with SDS version 2.1 (Applied Biosystems). Patients and
their first-degree relatives underwent a full genome screen in two
sequential experiments. Both screens were conducted using the
same set of microsatellite markers, evenly spaced by ∼10 cM (ABI
Prism Linkage Mapping Set MD-10 v. 2 and v. 2.5 [Applied Bio-
systems]). PCRs were performed according to the manufacturer’s
specified conditions. PCR products were separately pooled and
analyzed on ABI377 and ABI3100 automated sequencers (Applied
Biosystems). Because the genome scan had been performed with
different sequencing devices, the genetic data had to be merged.
The genotypic data was pooled using Pool_STR-1.1, on the basis
of the allele lengths and allele frequencies observed in each
group.50 Two independent technicians read the results from the
sequencers, and a third reader resolved the discordant results.
Only the markers with a discordance proportion !5% were se-
lected for further analysis ( ). Genotyping errors leadingNp 402
to Mendelian inconsistencies were detected using PedCheck (Stat-
gen).51 Unlikely double-recombination events were detected us-
ing Merlin.52 Definitive genotyping errors and unlikely genotypes
were rechecked using the data from the laboratory. Regions linked
to late-onset AD were later fine typed by placing 45 additional
microsatellite markers between those from the initial set, at a
distance of 1–5 cM.
SNPs in the linkage regions were selected from the 250K Nsp
array of the GeneChip Human Mapping 500K Array Set (Affy-
metrix). Genomic DNA was extracted from whole-blood samples
drawn at the baseline examination, with use of the salting-out
method.49 The 250K Nsp array from Affymetrix was used to de-
termine genotypes. The chips were run and analyzed according
to the manufacturer’s protocols. A total of 4,173 SNPs were se-
lected for the association test on the basis of the following criteria:
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Figure 3. Multipoint LOD and HLOD scores for each autosome in
the genome screen of late-onset AD. The legend is available in its
entirety in the online edition of The American Journal of Human
Genetics.
Table 4. Regions with Genomewide Empirically Significant
or Suggestive Linkage after Fine Mapping
Chromosome
and Marker
Position
(cM) LOD HLOD a
Region(s) Identified
Elsewherea
1A:
D1S498 164 5.1 5.2 .9 A,25 D,26 F,56 and G22
D1S305 167 4.5 4.5 1.0
1B:
D1S218 201 2.6 4.0 .6 A,25 D,26 F,56 and G22
D1S366 208 2.7 3.5 .6
3:
D3S1549 151 2.8 3.6 .6 B57
D3S1569 158 4.3 4.4 .8
10:
D10S1686 105 3.7 3.7 1.0 C,18 E,19 F,56 G,22 H,27 and I24
D10S185 116 4.2 4.2 1.0
11b:
D11S4151 127 .3 2.8 .4 G22
D11S4131 138 1.3 3.1 .5
D11S1320 142 1.6 3.3 .6
D11S968 148 .3 2.0 .5
NOTE.—Significant values are shown in bold.
a Overlaps with regions reported with suggestive linkage or significant
association in previous genome screens. Note that region B was screened
for only two chromosomes.
b Included to confirm a recent report about the SORL1 gene.30
(1) position within the regions that show significant or suggestive
evidence of linkage after fine mapping, (2) minor-allele frequency
2.5%, (3) P value for Hardy-Weinberg equilibrium test .01,
and (4) call rate 95%.
Statistical Analysis
In linkage analysis, we assumed a dominant model of inheritance
with age-dependent penetrance. Seven liability classes were de-
fined on the basis of age (in years): !65, 65–69, 70–74, 75–79,
80–84, 85–90, and 190. For each age group j, age-dependent pop-
ulation prevalence was obtained from the Rotterdam Study.1Pj
The disease-gene penetrance, , of the jth age group can be es-fj
timated as
PAF# Pjf p ,j 2q  2q(1 q)
where PAF is the population-attributable fraction—that is, the
proportion of the population prevalence that can be explained
by the studied gene (10% assumed)—and q is the disease-allele
frequency (1% assumed). The estimated penetrance for each de-
fined age group is shown in table 2. Marker-allele frequencies
were estimated on the basis of 144 chromosomes from unaffected
elderly GRIP population members (age at last examination 65
years). For small pedigrees (bits 18), we used the exact calcu-
lation of multilocus likelihood, the Lander-Green algorithm im-
plemented in GENEHUNTER 2.0.53 For larger pedigrees, we used
Markov chain–Monte Carlo estimation methods implemented in
SIMWALK 2.91 (Statgen). Overall LOD scores and heterogeneity
LOD (HLOD) scores were computed by combining results per
family with use of standard formulas, such as
HLODp log (maxLR) ,10
where maxLR is maximized with respect to a, the proportion of
the linked families, yielding maximum-likelihood estimate ,aˆ
n
ˆ ˆmaxLRp (aLR  1a) . i
ip1
Haplotypes were reconstructed on the basis of the genotypes
of patients, spouses of patients, and their offspring, with the Mer-
lin package.52 These families are further expanded to depict the
haplotype sharing of other patients who are relatively closely
related to the patients in the families with high LOD scores but
who were assigned to different families in the pedigree-splitting
procedure.
Breaking pedigrees may increase the possibility of spurious link-
age findings.54 Therefore, we estimated the threshold for statistical
significance by use of simulations. To evaluate genomewide type
I error, we simulated our genome scan 100 times. We used the
complete pedigree, including all 4,645 members, for marker sim-
ulation. Unlinked markers were dropped in the complete pedi-
gree. Number of markers, intermarker distances, and marker-allele
frequencies were simulated according to the typed marker set.
We performed linkage analysis using the split subpedigrees. Dis-
ease-allele frequency, liability classes, genetic model, and pene-
trances were the same as those we used later in the actual linkage
analysis. Genotypes of untyped individuals were set to “missing.”
For each genome screen, the highest HLOD score was stored.
Cumulative density function of the obtained 100 maximum HLOD
scores approximates the distribution of the genomewide type I
error rates. Our simulations showed that an HLOD score of 3.64
corresponds to a genomewide type I error rate of 5% and that an
HLOD of 2.11 corresponds to a genomewide type I error of 50%
(table 3).
We used linear regression to test for association between a single
SNP with a single cognitive trait. In accordance with Affymetrix
annotation, SNP genotypes were coded as , , and0p AA 1p AB
, where A represents the allele in lower alphabetical order2p BB
and B represents the other allele. Thus, in the case of a CrT
change where T is the minor allele, C is coded as the A allele and
T as the B allele, whereas, for a TrC change where C is the minor
allele, A denotes the C allele and B denotes the T allele. In the
model, we adjusted for age, sex, intelligence, and highest edu-
cation. Because a causal SNP (or a SNP in linkage disequilibrium
[LD] with the causal SNP) is likely to be associated with multiple
cognitive domains, we used the Fisher product method for com-
bining the findings of all cognitive tests.55 Because the SNPs that
are in LD and cognitive traits are also correlated, we used a per-
mutation method to evaluate significance level for each SNP em-
pirically (500,000 replicates). To break the associations between
the markers and traits while keeping the correlations between
traits and the LD pattern between markers, we permuted the vec-
tors of individuals’ traits (scores of cognitive tests and covariates)
among individuals, without replacement. For each permutation,
22
Figure 4. Multipoint LOD (blue) and HLOD (pink) scores for chromosomes 1, 3, 10, and 11 in the genome screen of late-onset AD
after fine typing. Marker locations are given in Kosambi centimorgans.
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Table 5. Select SNPs in the Regions Linked to AD
Chromosome
Start End No. of SNPs
Marker
Marshfield
(cM) SNP
Physical
Position
(bp) Marker
Marshfield
(cM) SNP
Physical
Position
(bp) Initial
After
QCa
1q21 D1S514 152.5 rs2790308 141501392 D1S2635 165.6 rs16827466 156462773 828 585
1q25 D1S218 191.5 rs17838246 171261041 D1S466 198.5 rs16860717 179972352 750 584
3q23 D3S1549 151.5 rs7632392 139168654 D3S3626 164.3 rs10513332 149350824 954 769
10q22-24 D10S580 96.7 rs7101263 77715269 D10S205 125.4 rs12765878 105659612 2,518 2,006
11q25 D11S4131 138.6 rs1526562 131160829 D11S968 147.8 rs7936592 133620325 260 229
a QCpquality control.
we tested for association between SNPs in each region and cog-
nitive traits, and we derived corresponding Fisher products. The
cumulative density function of all Fisher products for each region
empirically approximates the regionwide type I error rate. There-
fore, the empirical P value for each SNP can be defined as the
probability of observing an equal or smaller regionwide Fisher
product by chance.
Results
For linkage analysis, we clustered all patients and 170 first-
degree relatives into 35 subpedigrees (fig. 2). During ped-
igree splitting, distant ancestors who have no phenotypic
and genotypic information and do not contribute to link-
age information were discarded. The resultant subpedi-
grees contained a total of 1,227 individuals. The charac-
teristics of the subpedigrees are shown in table 1.
Multipoint LOD and HLOD score plots for the initial
scan are shown in figure 3. A total of eight regions showed
suggestive linkage (LOD or ), of which theHLOD 1 2.11
chromosome 1 region exceeded the threshold of 3.64
( at marker D1S484). These eight regions wereLODp 4.1
fine typed with 45 additional markers and include chro-
mosome 1 (14 additional markers), chromosome 3 (10 ad-
ditional markers), chromosome 5 (2 additional markers),
chromosome 6 (5 additional markers), chromosome 7 (3
additional markers), chromosome 10 (6 additional mark-
ers), chromosome 11 (2 additional markers), and chro-
mosome 18 (3 additional markers).
Table 4 shows the regions for which the evidence of
linkage remained significant or suggestive ( ) af-LOD 1 2.11
ter fine mapping. AD remained linked to three known
regions, two on chromosome 1 (fig. 4A) and one on chro-
mosome 10 (fig. 4C). The maximum HLOD at 1q21 was
5.2 at D1S498. This is the highest peak over the genome.
The maximum HLOD at 1q25 was 4.0 at D1S218 and 4.2
at D10S185. References for the previously identified re-
gions are shown in table 4. In addition to the known
regions, we found genomewide significant evidence of
linkage of AD to a region on chromosome 3 that spanned
18 cM from D3S3514 to D3S3626 and reached a maximum
HLOD of 4.4 at D3S1569 (fig. 4B). This is the second high-
est peak over the genome. In table 4, we also included
chromosome 11, in which a new gene (SORL1) responsible
for AD was recently reported.30 There is suggestive evi-
dence of linkage of AD to chromosome 11 (HLODp 3.3
at D11S1320) (fig. 4D), which overlaps with a region re-
ported earlier. On chromosome 11, the HLOD at the po-
sition of SORL1 (118 cM) is 1.1.
Haplotype analysis showed that the two linkage peaks
on chromosome 1q21 and 1q25 are explained by different
haplotypes segregating in different families. On chromo-
some 1q21, we identified a 15-cM region shared by four
patients in family 1 and six other closely related patients
who were assigned to different pedigrees for computa-
tional reasons in the process of pedigree splitting (fig. 5A).
The 21-cM haplotype of 1q25 segregates in family 3 (four
patients) and is shared by four other closely related pa-
tients who were assigned to different subpedigrees (fig.
5B). Six patients from family 9 and six closely related pa-
tients carry the haplotype of chromosome 3q23 (18 cM),
as shown in figure 5C. The linkage of AD to the region
on chromosome 10 was based on moderate contributions
from multiple families with different haplotypes. There
is not a single haplotype segregating in this region (data
not shown). For chromosome 11q24, which showed sug-
gestive linkage, we observed a single haplotype (3.4 cM)
shared by four patients from family 4 and two additional
closely related patients (fig. 5D).
Next, we tested for association between cognitive func-
tion and a set of 4,173 SNPs within regions 1q21, 1q25,
3q23, 10q22-24, and 11q25, using an independent sample
consisting of 197 individuals from the GRIP population
(table 5). All of the linked regions except 1q21 contain at
least one SNP showing significant association with use of
an empirical P value of .05 (table 6). Statistically, the most
significant SNP is rs7071717 at 10q23, both for the nom-
inal P value in a single test ( , by Stroop test)Pp .000005
and for the empirical Fisher product ( ), whichPp .002
combines the results of cognitive tests and adjust for mul-
tiple testing. This SNP, together with rs17129662 and
rs11185978, is in a range of 80 kb and shows evidence of
association with the Stroop test, TMTB, and semantic (ex-
cept rs17129662) and phonological fluency, all of which
are subdomains of executive function. These three SNPs
are 2–80 kb downstream of the MPHOSPH1 gene encoding
M phase phosphoprotein 1 and ∼760 kb upstream of the
5-hydroxytryptamine receptor 7 (HTR7 [MIM 182137])
gene. Another SNP, rs4110517 at 10q23, showed associa-
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tion with semantic ( ) and phonological (Pp .00003 Pp
) fluency (empirical ). This SNP is 37.6 kb down-.04 Pp .02
stream of the CYP2C19 (MIM 124020) gene and 48.1 kb
upstream of the CYP2C9 (MIM 601130) gene. At 1q25,
the SNP rs2584820 was associated with the Stroop test
( ) and phonological fluency ( ), with anPp .0001 Pp .03
empirical P value of .04. This SNP is in intron 4 of the
regulator of G-protein signaling like 2 (RGSL2) gene. Two
other SNPs in this region showed association with the
TMTB ( ; empirical ). They are 4 kb down-Pp .0003 Pp .04
stream of the C1orf49 gene and 149 kb upstream of
the Ral GEF with PH domain and SH3 binding motif 2
(RALGPS2) gene. At 3q23, the SNP rs952797 was asso-
ciated with the Stroop test ( ), the Block testPp .0001
( ), and learning ( ). When all tests werePp .0002 Pp .06
evaluated simultaneously, the association was significant
(empirical ). This SNP is 126 kb downstream of thePp .04
gene encoding nicotinamide nucleotide adenylyltransfer-
ase 3 (NMNAT3 [MIM 608702]) and 131 kb upstream of
the gene encoding calsyntein 2 (CLSTN2). SNP rs11223225
(CrT) at 11q25 showed a consistent allelic effect across
key cognitive domains for AD, including learning, delayed
recall, and concept shifting (Stroop and TMTB), where the
minor allele of this SNP is associated with poorer perfor-
mance on delayed recall ( ), learning ( ),Pp .0004 Pp .03
the Stroop test ( ), TMTB ( ), and the BlockPp .02 Pp .09
test ( ). When the effect of various tests was com-Pp .07
bined, the overall empirical P value was .03. This SNP is
in intron 1 of the gene encoding opioid binding pro-
tein/cell adhesion molecule-like (OPCML [MIM 600632]).
Four close SNPs—rs1629316, rs1547897, rs1122931, and
rs11222932—at 11q25 were associated with TMTB and
phonological fluency. These SNPs are in intron 1 of the
gene encoding neurotrimin (HNT [MIM 607938]). The
OPCML and HNT genes are !80 kb apart.
Discussion
This study confirms earlier findings suggesting linkage of
AD to a wide region that spans chromosome 1q21-31.25,
26,56 The 1q21 region yielded the most significant evidence
of linkage over the genome in our study ( ).HLODp 5.2
This region was not replicated when testing for association
with cognition in a series of 197 distantly related subjects.
Although we cannot exclude the possibility of a false-pos-
itive finding, given the strength of the linkage signal and
previous evidence, it is more likely that there is a rare
mutation in a major gene in this region that could not be
identified by association analysis in a small sample. This
region contains the NCSTN gene, which binds presenilin
and is required for g-secretase activity and Ab generation.58
Mutations in this gene have been found to be related to
early-onset AD, and we have reported association in a sub-
group of patients with familial early-onset AD, particularly
in those who lack the APOE*4 allele.59 We have sequenced
all the exons and splice sites of this gene in six patients
but have not found variants. Another obvious candidate
gene in this region is the gene encoding C-reactive protein
(CRP [MIM 123260]), which acts as a scavenger for chro-
matin released by dead cells during the acute inflamma-
tory process.60 We also sequenced the exons and splice sites
of this gene in seven patients (5088, 5167, 5115, 5140,
5393, 5023, and 5394) (fig. 5A) and found that all patients
except patients 5167 and 5393 carry the rare alleles of
SNPs rs1130864 (CrT) and rs1417938 (TrA). The SNP
rs1130864 has been reported as a tagging SNP for a hap-
lotype associated with higher levels of CRP.61,62 We spe-
cifically tested the association of polymorphisms in CRP
with cognitive function but failed to show any association
(data not shown). Since CRP is a key protein involved in
inflammation, a key process in life by itself, a major mu-
tation in CRP seams unlikely for late-onset diseases, which
suggests that another gene in the region may explain our
high LOD score. In the 1q25 region, there was a second
segregating haplotype. This region was confirmed in our
association analysis by a SNP in intron 4 of RGSL2, which
may be involved in the G-protein coupled receptor protein
signaling pathway. Also, two SNPs upstream showed evi-
dence of association. However, these SNPs were significant
only for the TMTB and are intergenic, making it more
likely that RGSL2 is the relevant gene in the 1q25 region.
The second highest linkage signal was found at chro-
mosome 3q22-24. This region was reported earlier to be
linked to AD without tau pathology in a study of a small
family with four affected relatives.57 A significant LOD
score of 4.1 between markers D3S1569 and D3S3554 was
reported, whereas, in our study, D3S1569 is also the
marker that gives the highest HLOD over chromosome 3.
In the study by Poduslo et al.,57 no genomewide screen
was conducted; only chromosomes 3 and 17 were screened,
since the disease was expected to be related to frontotem-
poral dementia (FTD) and the phenotype was apparently
considered to be compatible with that of FTD. Since we
do not have pathology information for our patients, we
cannot exclude the possibility that some of our patients
also suffer from this atypical form of AD. However, all
patients were carefully evaluated by a neurologist who
specializes in FTD. A recent linkage-based genome scan of
Caribbean Hispanic families revealed a new locus on chro-
mosome 3q28, with a 2-point LOD score of 3.09 at marker
D3S2418.35 However, this region is ∼50 cM downstream
of the region we identified in our study. The linked region
on chromosome 3q22-24 contains various possible can-
didate genes, including the TF gene, the gene encoding
for butyrylcholinesterase (BCHE [MIM 177400]), the ne-
prilysin gene (MME [MIM 120520]), and the somatostatin
gene (SST [MIM 182450]). We screened these genes for
mutations, but no variants were found. The SNP rs952797
at 3q23 was consistently associated with cognitive func-
tion in the 197 unrelated subjects from the GRIP popu-
lation. This SNP is 126 kb downstream of the NMNAT3
gene encoding nicotinamide nucleotide adenylyltransfer-
ase 3 (NAD3). The coenzyme NAD and its derivatives are
involved in hundreds of metabolic redox reactions and
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are used in protein ADP-ribosylation, histone deacetyla-
tion, and in some Ca2-signaling pathways. NMNAT is a
central enzyme in NAD biosynthesis, catalyzing the con-
densation of nicotinamide mononucleotide or nicotinic
acid mononucleotide with the AMP moiety of ATP to form
NAD or NaAD (Zhang et al.63); thus, the NMNAT3 gene
may relevant to AD. The SNP rs952797 is 131 kb upstream
of the CLSTN2 gene. It has been reported recently that
SNP rs6439886, a common TrC substitution within the
first intron of CLSTN2, was significantly associated with
memory performance.64 Our SNP rs952797 is 160 kb up-
stream of the reported SNP.
Chromosome 10q22-24 is the third highest peak over
the genome. This finding is consistent with previous find-
ings about AD15,20–22,24 and plasma amyloid b42 levels.65
Our finding of linkage to late-onset AD at 10q22-24 is the
first replication with use of a data set fully independent
of the National Institute of Mental Health (NIMH) sample.
So far, it has been difficult to identify the causal muta-
tion(s) in this region. A series of genes has been densely
genotyped, and several genes have been noted to be sus-
ceptibility genes for AD, including IDE, CH25H (MIM
604551), PLAU (MIM 191840), and LIPA (MIM 278000).
In our linkage analysis, there was not a single haplotype
segregating in the region, suggesting that multiple mu-
tations in one or multiple genes may contribute to the
linkage. In our association analysis, the most significant
evidence of association with cognitive function was seen
for this region. Three SNPs:—rs17129662, rs11185978,and
rs7071717, together at 91.7 Mb—showed association with
multiple cognitive domains in the 197 unrelated subjects
from the GRIP population. These SNPs are intergenic SNPs
of known genes. All three SNPs are !1 Mb upstream of the
CH25H gene and the LIPA gene and !3 Mb downstream
of the IDE gene. The genes most closely flanking these
SNPs are the MPHOSPH1 gene and the HTR7 gene, which
encodes 5-hydroxytryptamine receptor 7. These two genes,
however, have not been extensively investigated. Another
associated SNP, rs4110517 at 116.8 cM, is surrounded by
four similar genes—CYP2C18 (MIM 601131), CYP2C19,
CYP2C9, and CYP2C8 (MIM 601129)—in a range of !350
kb. Since no significant association was found between
the CYP2C19 gene and patients with familial AD in a pre-
vious study,66 it is more likely that the SNP rs4110517 is
in LD with the causal gene(s) in the region.
We also found suggestive evidence of linkage to chro-
mosome 11q25. Blacker et al.22 previously described this
region in their study of the NIMH sample, including 437
families with AD. Recent evidence suggests the SORL1
gene may be responsible.30 Our linkage peak is, however,
∼23 cM downstream of the SORL1 gene. We specifically
tested the association between polymorphisms flanking
SORL1 and cognitive function but failed to detect consis-
tent associations (data not shown), suggesting that our
linkage peak may be explained by other gene(s). The
association for SNP rs11223225, a CrT substitution at
11q25, is one of the most promising results from our as-
sociation analysis. The T allele of this SNP is consistently
associated with reduced cognitive performance on multi-
ple domains, and this SNP is an intronic SNP of the OPCML
gene, which encodes the opioid-binding protein. There
is evidence that the opioidergic system is affected in
AD.67 Furthermore, performance on immediate memory
and mental flexibility tasks has been suggestively linked
to 11q25 in a recent genomewide linkage study of 260
families.68 Four other close SNPs at 11q25 also showed
association with cognitive function. These SNPs are in in-
tron 1 of the HNT gene, which encodes neurotrimin. No-
tably, the OPCML and HNT genes are separated by !80 kb.
In summary, we confirmed two previously well-described
linkage regions for late-onset AD on chromosomes 1q21-
25 and 10q22-24. With cognitive function as an endo-
phenotype of AD, our study specifies the RGSL2, RALGPS2,
and C1orf49 genes at 1q25. Our analysis of chromosome
10q22-24 points to the HTR7, MPHOSPH1, and CYP2C
cluster. To our knowledge, this is the first genomewide
screen that showed significant linkage to chromosome
3q23 markers. For this region, our analysis identified the
NMNAT3 and CLSTN2 genes. Our findings confirm linkage
to chromosome 11q25. We were unable to confirm SORL1;
instead, our analysis points to the OPCML and HNT genes.
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The URLs for data presented herein are as follows:
AlzGene Database and Alzheimer Research Forum, http://www
.alzgene.org/
GENEHUNTER, http://linkage.rockefeller.edu/soft/gh/ (for multi-
point linkage analysis with the Lander-Green algorithm)
Merlin, http://www.sph.umich.edu/csg/abecasis/Merlin/
download/ (for detecting unlikely double-recombination events
and haplotype construction)
MGA, http://mga.bionet.nsc.ru/soft/index.html (for PedCut)
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.nlm.nih.gov/Omim/ (for PSEN1, PSEN2, APP, APOE, ACE,
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TFAM, TNF, SORL1, HTR7, CYP2C19, CYP2C9, NMNAT3,OPCML,
HNT, CRP, BCHE, MME, SST, CH25H, PLAU, LIPA, CYP2C18, and
CYP2C8)
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(v. 0.5, for drawing large pedigrees)
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detecting Mendelian errors] and SIMWALK [for multipoint link-
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